Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334316 · ClinicalTrials.gov registry record · Phase 2
Individualizing Corticosteroid Use in Pneumonia
A Phase 2 study of Pneumonia, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05334316: Recruiting Phase 2 study of Pneumonia, sponsored by Mayo Clinic.
NCT05334316 is a Phase 2 study of Pneumonia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05334316, a Phase 2 study of Pneumonia, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.
Primary Outcome
Number of eligible subjects that adhered to the timely initiation and daily corticosteroid treatment
Conditions Studied
Interventions
- DRUG Dexamethasone
Study Locations (1)
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT05334316 shows while recruiting
NCT05334316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Dexamethasone is the first listed.
NCT05334316 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05334316 about?
NCT05334316 is a clinical study titled "Individualizing Corticosteroid Use in Pneumonia". In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in ...
What is the current status of trial NCT05334316?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-11-01. Estimated completion is 2027-12.
What conditions does trial NCT05334316 study?
This clinical trial studies the following conditions: Pneumonia.
What interventions are being tested in trial NCT05334316?
The interventions under investigation include: Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05334316?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05334316 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05334316's enrollment target sits among peer trials
24 45th of 47 higher than 3 of 47 other Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
ACTIVE NOT RECRUITING · Phase 2
-
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
COMPLETED · Phase 2
-
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
COMPLETED · Phase 2
-
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
COMPLETED · Phase 2
-
Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI